Solid Biosciences (SLDB)
Advancing gene therapy candidates for Duchenne and other rare neuromuscular and cardiac diseases.
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 106.77% | 114.48M shares | |
|---|---|---|---|
| 163 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 8.99% | 9.64M shares | |
| 10 holders · as of Jul 7, 2026 | |||
| Adds to | 115.76% | ||
107.23M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (107.23M in the company's Sep 22, 2026 report, 98.45M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 115.76%; nothing is left for Other.
13F, as of Jun 30, 2026
163 holders · 114.48M shares · 43 new positions · 101 increased · 37 reduced · 27 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 12.04M | 11.23% | +2.70M | Aug 14, 2026 |
| Perceptive Advisors LLC | 11.91M | 11.10% | 0 | Aug 14, 2026 |
| Bain Capital Life Sciences Investors, LLC | 9.81M | 9.15% | 0 | Aug 14, 2026 |
| Siren, L.L.C. | 7.69M | 7.17% | 0 | Aug 13, 2026 |
| BlackRock, Inc. | 6.93M | 6.47% | +1.98M | Aug 7, 2026 |
| FMR LLC | 6.88M | 6.41% | +3.27M | Aug 13, 2026 |
| Armistice Capital, LLC | 4.28M | 3.99% | +1.08M | Aug 14, 2026 |
| State Street Corp | 4.18M | 3.89% | +3.05M | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P.incl. RA Capital Healthcare Fund, L.P., Peter Kolchinsky +1 more | 11.90% | 12.04M | 13D | Jun 24, 2026 |
| Perceptive Advisors LLCincl. Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. +1 more | 11.20% | 12.05M | 13D | Aug 14, 2026 |
| BCLS II Investco, LPincl. BCIP Life Sciences Associates, LP, BCLS II Equity Opportunities, LP +3 more | 8.80% | 8.60M | 13D | Mar 10, 2026 |
| Invus Public Equities, L.P. | 8.70% | 8.70M | 13G | May 5, 2026 |
| Commodore Capital LP | 7.60% | 5.83M | 13G | Feb 25, 2025 |
| Vestal Point Capital, LP | 7.50% | 5.82M | 13G | Feb 17, 2026 |
| Ryan Wilderincl. Vestal Point Capital, LP | 7.30% | 2.80M | 13G | Nov 14, 2024 |
| BlackRock, Inc. | 6.50% | 6.42M | 13G | Jul 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Feb 18, 2026 | Kevin Tanofficer: CFO & Treasurer | Sale | 5,404 | $5.82 | 99,422 |
| Feb 18, 2026 | Gabriel Brooksofficer: Chief Medical Officer | Sale | 0 | 89,466 | |
| Feb 18, 2026 | David T. Howtonofficer: Chief Operating Officer | Sale | 7,469 | $5.82 | 105,077 |
| Feb 18, 2026 | Paul Herzichofficer: Chief Technology Officer | Sale | 3,616 | $5.82 | 72,638 |
| Feb 18, 2026 | Ilan Ganotdirector | Sale | 2,658 | $5.82 | 27,474 |
| Feb 18, 2026 | Jessie Hanrahanofficer: Chief Regulatory Officer | Sale | 4,134 | $5.82 | 74,318 |
| Feb 18, 2026 | Alexander Cumbodirector, officer: President and CEO | Sale | 16,644 | $5.82 | 235,405 |
| Feb 4, 2026 | Paul Herzichofficer: Chief Technology Officer | Sale | 10,905 | $6.44 | 69,067 |
| Feb 4, 2026 | Jessie Hanrahanofficer: Chief Regulatory Officer | Sale | 12,348 | $6.44 | 70,327 |
| Feb 4, 2026 | Gabriel Brooksofficer: Chief Medical Officer | Sale | 12,616 | $6.44 | 84,092 |
House and Senate disclosures
Not reported.